Increases in [3H]Muscimol and [3H]Flumazenil Binding in the Dorsolateral Prefrontal Cortex in Schizophrenia Are Linked to α4 and γ2S mRNA Levels Respectively

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Verdurand, Mathieu ^a,d   Fillman, Stu G ^a,b,c   Shannon Weickert, Cynthia ^a,b,c   Zavitsanou, Katerina ^a,b,c  

^a SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA4; 4 AMINOBUTYRIC ACID A RECEPTOR BETA1; 4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 4 AMINOBUTYRIC ACID A RECEPTOR BETA3; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA1; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2L; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2S; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA3; FLUMAZENIL; MESSENGER RNA; MUSCIMOL; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; GABRA4 PROTEIN, HUMAN; GABRG2 PROTEIN, HUMAN;

ADULT; ARTICLE; AUTORADIOGRAPHY; BINDING SITE; BRAIN TISSUE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; PREFRONTAL CORTEX; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGRESSION ANALYSIS; RNA ISOLATION; SCHIZOPHRENIA; AGED; CASE CONTROL STUDY; CHEMISTRY; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; PROTEIN SUBUNIT;

ADULT; AGED; ALLOSTERIC SITE; AUTORADIOGRAPHY; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FLUMAZENIL; GABA MODULATORS; GABA-A RECEPTOR AGONISTS; HUMANS; MALE; MIDDLE AGED; MUSCIMOL; PREFRONTAL CORTEX; PROTEIN SUBUNITS; RECEPTORS, GABA-A; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 84872187097     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052724     Document Type: Article

References (58)

1. Daskalakis ZJ, Fitzgerald PB, Christensen BK, (2007) The role of cortical inhibition in the pathophysiology and treatment of schizophrenia. Brain Research Reviews 56: 427-442.
2. Olsen RW, Sieghart W, (2008) International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacological Reviews 60: 243-260.
3. Boileau AJ, Pearce RA, Czajkowski C, (2010) The short splice variant of the gamma 2 subunit acts as an external modulator of GABA(A) receptor function. Journal of Neuroscience 30: 4895-4903.
4. Connolly CN, Uren JM, Thomas P, Gorrie GH, Gibson A, et al. (1999) Subcellular localization and endocytosis of homomeric gamma2 subunit splice variants of gamma-aminobutyric acid type A receptors. Molecular and Cellular Neurosciences 13: 259-271.
5. Hanson SM, Czajkowski C, (2008) Structural mechanisms underlying benzodiazepine modulation of the GABA(A) receptor. Journal of Neuroscience 28: 3490-3499.
6. Smith GB, Olsen RW, (1995) Functional domains of GABAA receptors. Trends in Pharmacological Sciences 16: 162-168.
7. Sanna E, Mascia MP, Klein RL, Whiting PJ, Biggio G, et al. (1995) Actions of the general anesthetic propofol on recombinant human GABAA receptors: influence of receptor subunits. The Journal of Pharmacology and Experimental Therapeutics 274: 353-360.
8. Hill-Venning C, Belelli D, Peters JA, Lambert JJ, (1997) Subunit-dependent interaction of the general anaesthetic etomidate with the gamma-aminobutyric acid type A receptor. British Journal of Pharmacology 120: 749-756.
9. Hevers W, Lüddens H, (1998) The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Molecular Neurobiology 18: 35-86.
10. Rudolph U, Knoflach F, (2011) Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nature Reviews Drug Discovery 10: 685-697.
11. Duncan CE, Webster MJ, Rothmond DA, Bahn S, Elashoff M, et al. (2010) Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia. Journal of Psychiatric Research 44: 673-681.
12. Beneyto M, Abbott A, Hashimoto T, Lewis DA, (2011) Lamina-specific alterations in cortical GABA(A) receptor subunit expression in schizophrenia. Cerebral Cortex 21: 999-1011.
13. Fillman SG, Duncan CE, Webster MJ, Elashoff M, Weickert CS, (2010) Developmental co-regulation of the beta and gamma GABAA receptor subunits with distinct alpha subunits in the human dorsolateral prefrontal cortex. International Journal of Developmental Neuroscience: The Official Journal of the International Society for Developmental Neuroscience 28: 513-519.
14. Fatemi SH, Reutiman TJ, Folsom TD, Rooney RJ, Patel DH, et al. (2010) mRNA and protein levels for GABAAalpha4, alpha5, beta1 and GABABR1 receptors are altered in brains from subjects with autism. Journal of Autism and Developmental Disorders 40: 743-750.
15. Benes FM, Khan Y, Vincent SL, Wickramasinghe R, (1996) Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. Synapse (New York, NY) 22: 338-349.
16. Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP, (1992) Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. The Journal of neuroscience: the official journal of the Society for Neuroscience 12: 924-929.
17. Benes FM, Vincent SL, Marie A, Khan Y, (1996) Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75: 1021-1031.
18. Dean B, Hussain T, Hayes W, Scarr E, Kitsoulis S, et al. (1999) Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. Journal of Neurochemistry 72: 1593-1599.
19. Deng C, Huang X-F, (2006) Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia. Experimental Brain Research (Experimentelle Hirnforschung Expérimentation cérébrale) 168: 587-590.
20. Hanada S, Mita T, Nishino N, Tanaka C, (1987) [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sciences 40: 259-266.
21. Newell KA, Zavitsanou K, Jew SK, Huang X-F, (2007) Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31: 225-233.
22. Owen F, Cross AJ, Crow TJ, Lofthouse R, Poulter M, (1981) Neurotransmitter receptors in brain in schizophrenia. Acta Psychiatrica Scandinavica Supplementum 291: 20-28.
23. Volk DW, Pierri JN, Fritschy J-M, Auh S, Sampson AR, et al. (2002) Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cerebral Cortex 12: 1063-1070.
24. Benes FM, Wickramasinghe R, Vincent SL, Khan Y, Todtenkopf M, (1997) Uncoupling of GABA(A) and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain. Brain Research 755: 121-129.
25. Kiuchi Y, Kobayashi T, Takeuchi J, Shimizu H, Ogata H, et al. (1989) Benzodiazepine receptors increase in post-mortem brain of chronic schizophrenics. European Archives of Psychiatry and Neurological Sciences 239: 71-78.
26. Pandey GN, Conley RR, Pandey SC, Goel S, Roberts RC, et al. (1997) Benzodiazepine receptors in the post-mortem brain of suicide victims and schizophrenic subjects. Psychiatry Research 71: 137-149.
27. Busatto GF, Pilowsky LS, Costa DC, Ell PJ, David AS, et al. (1997) Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. The American Journal of Psychiatry 154: 56-63.
28. Ball S, Busatto GF, David AS, Jones SH, Hemsley DR, et al. (1998) Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: a 123I-iomazenil SPET study. BPS 43: 107-117.
29. Abi-Dargham A, Laruelle M, Krystal J, D'Souza C, Zoghbi S, et al. (1999) No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 20: 650-661.
30. McLeod MC, Scarr E, Dean B, (2010) Effects of benzodiazepine treatment on cortical GABA(A) and muscarinic receptors: studies in schizophrenia and rats. Psychiatry Research 179: 139-146.
31. Impagnatiello F, Guidotti AR, Pesold C, Dwivedi Y, Caruncho H, et al. (1998) A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 95: 15718-15723.
32. Huntsman MM, Tran BV, Potkin SG, Bunney WE, Jones EG, (1998) Altered ratios of alternatively spliced long and short gamma2 subunit mRNAs of the gamma-amino butyrate type A receptor in prefrontal cortex of schizophrenics. Proceedings of the National Academy of Sciences of the United States of America 95: 15066-15071.
33. Hashimoto T, Arion D, Unger T, Maldonado-Avilés JG, Morris HM, et al. (2008) Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Molecular Psychiatry 13: 147-161.
34. Lewis DA, Hashimoto T, Morris HM, (2008) Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia. Neurotoxicity Research 14: 237-248.
35. Weickert CS, Sheedy D, Rothmond DA, Dedova I, Fung S, et al. (2010) Selection of reference gene expression in a schizophrenia brain cohort. The Australian and New Zealand Journal of Psychiatry 44: 59-70.
36. Harper CG, Kril JJ, Daly JM, (1988) Brain shrinkage in alcoholics is not caused by changes in hydration: a pathological study. Journal of Neurology, Neurosurgery, and Psychiatry 51: 124-127.
37. Hand KS, Baird VH, Van Paesschen W, Koepp MJ, Revesz T, et al. (1997) Central benzodiazepine receptor autoradiography in hippocampal sclerosis. British Journal of Pharmacology 122: 358-364.
38. Wong J, Hyde TM, Cassano HL, Deep-Soboslay A, Kleinman JE, et al. (2010) Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia. Neuroscience 169: 1071-1084.
39. Herb A, Wisden W, Lüddens H, Puia G, Vicini S, et al. (1992) The third gamma subunit of the gamma-aminobutyric acid type A receptor family. Proceedings of the National Academy of Sciences of the United States of America 89: 1433-1437.
40. Lüddens H, Seeburg PH, Korpi ER, (1994) Impact of beta and gamma variants on ligand-binding properties of gamma-aminobutyric acid type A receptors. Molecular Pharmacology 45: 810-814.
41. Ymer S, Draguhn A, Wisden W, Werner P, Keinänen K, et al. (1990) Structural and functional characterization of the gamma 1 subunit of GABAA/benzodiazepine receptors. The EMBO Journal 9: 3261-3267.
42. Baer K, Essrich C, Balsiger S, Wick MJ, Harris RA, et al. (2000) Rescue of gamma2 subunit-deficient mice by transgenic overexpression of the GABAA receptor gamma2S or gamma2L subunit isoforms. The European Journal of Neuroscience 12: 2639-2643.
43. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, et al. (1995) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Archives of General Psychiatry 52: 258-266.
44. Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, et al. (2000) Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Archives of General Psychiatry 57: 1061-1069.
45. Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, et al. (2005) Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. Journal of Neuroscience 25: 372-383.
46. Straub RE, Lipska BK, Egan MF, Goldberg TE, Callicott JH, et al. (2007) Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Molecular Psychiatry 12: 854-869.
47. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA, (2000) Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Archives of General Psychiatry 57: 237-245.
48. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA, (1998) A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 95: 5341-5346.
49. Whittington MA, Traub RD, (2003) Interneuron diversity series: inhibitory interneurons and network oscillations in vitro. Trends in Neurosciences 26: 676-682.
50. Vinkers CH, Mirza NR, Olivier B, Kahn RS, (2010) The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline. Expert Opinion on Investigational Drugs 19: 1217-1233.
51. Knoflach F, Benke D, Wang Y, Scheurer L, Lüddens H, et al. (1996) Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2. Molecular Pharmacology 50: 1253-1261.
52. Wolkowitz OM, Pickar D, (1991) Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. The American Journal of Psychiatry 148: 714-726.
53. Haw C, Stubbs J, (2007) Benzodiazepines-a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital. Journal of Psychopharmacology (Oxford, England) 21: 645-649.
54. Farrant M, Nusser Z, (2005) Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nature Reviews Neuroscience 6: 215-229.
55. Glykys J, Mann EO, Mody I, (2008) Which GABAA receptor subunits are necessary for tonic Inhibition in the hippocampus? Journal of Neuroscience 28: 1421-1426.
56. Flynn G, Alexander D, Harris A, Whitford T, Wong W, et al. (2008) Increased absolute magnitude of gamma synchrony in first-episode psychosis. Schizophrenia Research 105: 262-271.
57. Kellendonk C, Simpson EH, Kandel ER, (2009) Modeling cognitive endophenotypes of schizophrenia in mice. Trends in Neurosciences 32: 347-358.
58. Strous RD, Stryjer R, Maayan R, Gal G, Viglin D, et al. (2007) Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology 32: 96-105.